keyword
MENU ▼
Read by QxMD icon Read
search

Truvada

keyword
https://www.readbyqxmd.com/read/28857829/were-we-prepared-for-prep-five-years-of-implementation
#1
Michael Weinstein, Otto O Yang, Adam Carl Cohen
: While the overall incidence of HIV infections in the United States (US) has decreased in recent years, certain populations remain particularly vulnerable, including racial/ethnic minorities, adolescents/young adults, and people in the southern US [1]. The Centers for Disease Control and Prevention (CDC) stated strategy to combat new infections includes a combination of "cost-effective, scalable interventions based on current science" [2]. In July 2012, the US Food and Drug Administration (FDA) approved daily oral combination tenofovir/emtricitabine ("Truvada") for pre-exposure prophylaxis (PrEP) in at-risk uninfected adults, with subsequent endorsement as blanket policy by the CDC in May 2014 [3]...
August 28, 2017: AIDS
https://www.readbyqxmd.com/read/28847059/-acceptability-of-pre-exposure-hiv-prophylaxis-clinical-trial-among-msm-in-shenyang-city
#2
X Mao, H Yu, Q H Hu, J Zhang, Z X Chu, Y N Wang, W Q Geng, Y J Jiang, J J Xu
Objective: To investigate the acceptability and related factors of an "on-demand" pre-exposure prophylaxis (PrEP) to prevent HIV transmission among MSM in Shenyang. Methods: MSM recruited by non-probability sampling method and questionnaire survey conducted by investigators to collect information on social and behavioral characteristics, awareness of PrEP, Truvada and the acceptability of two different PrEP-based trials. Multivariate logistic regression was employed for statistical analysis. Results: Among the 292 respondents, 34...
August 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28657199/interprep-internet-based-pre-exposure-prophylaxis-with-generic-tenofovir-disoproxil-fumarate-emtrictabine-in-london-analysis-of-pharmacokinetics-safety-and-outcomes
#3
X Wang, N Nwokolo, R Korologou-Linden, A Hill, G Whitlock, I Day-Weber, M O McClure, M Boffito
OBJECTIVES: The National Health Service in England (NHS England) does not provide pre-exposure prophylaxis (PrEP) against HIV, forcing people to purchase generic versions on the internet. However, there are concerns about the authenticity of medicines purchased online. We established an innovative service offering plasma tenofovir (TFV) and emcitrabine (FTC) therapeutic drug monitoring for people buying generic PrEP online, to ensure that drug concentrations in vivo were consistent with those of propriety brands and previously published data...
June 28, 2017: HIV Medicine
https://www.readbyqxmd.com/read/28639995/brief-report-recovery-of-bone-mineral-density-after-discontinuation-of-tenofovir-based-hiv-pre-exposure-prophylaxis
#4
David V Glidden, Kathleen Mulligan, Vanessa McMahan, Peter L Anderson, Juan Guanira, Suwat Chariyalertsak, Susan P Buchbinder, Linda Gail Bekker, Mauro Schechter, Beatriz Grinsztejn, Robert M Grant
BACKGROUND: Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous reports suggest that these changes may be reversible after discontinuation of TDF. SETTING: A metabolic substudy of 498 participants in a randomized, placebo-controlled HIV prevention trial of oral coformulated TDF with emtricitabine (TDF/FTC, Truvada) for HIV pre-exposure prophylaxis (PrEP) enrolling a global sample of men who have sex with men and trans women...
October 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28423992/secrecy-empowerment-and-protection-positioning-prep-in-kwazulu-natal-south-africa
#5
Eliza Govender, Leila Mansoor, Kate MacQueen, Quarraisha Abdool Karim
The release of World Health Organisation guidelines recommending the prophylactic use of daily Truvada(®) for all populations at high risk of acquiring HIV opens the way for implementation of oral pre-exposure prophylaxis (PrEP). The impact of new prevention technologies is, however, dependent on demand creation strategies such as user awareness, acceptability and access, which in turn are influenced by sociocultural and gender norms. This study was conducted in three locations in KwaZulu-Natal, urban, rural and peri-urban, with six participatory workshops...
April 20, 2017: Culture, Health & Sexuality
https://www.readbyqxmd.com/read/28370177/blood-safety-implications-of-donors-using-hiv-pre-exposure-prophylaxis
#6
C R Seed, H Yang, J F Lee
HIV pre-exposure prophylaxis (PrEP) is the use of one or more antiretroviral medications (in combination) to prevent HIV infection. The most commonly used PrEP medication (Truvada(®) , Gilead Sciences, Inc.) acts by inhibiting HIV-1 reverse transcriptase. If someone who is using PrEP unknowingly becomes HIV infected (termed 'PrEP breakthrough infection'), there may be suppressed viral replication resulting in a virus level undetectable by the most sensitive HIV NAT. Failure to seroconvert and seroreversion (loss of previously detectable HIV antibodies) have also both been observed with 2nd, 3rd and 4th generation screening immunoassays, as well as Western blot assays...
March 31, 2017: Vox Sanguinis
https://www.readbyqxmd.com/read/28369381/randomized-controlled-trial-of-the-tolerability-and-completion-of-maraviroc-compared-with-kaletra%C3%A2-in-combination-with-truvada%C3%A2-for-hiv-post-exposure-prophylaxis-mipep-trial
#7
Ana Milinkovic, Paul Benn, Alejandro Arenas-Pinto, Nataliya Brima, Andrew Copas, Amanda Clarke, Martin Fisher, Gabriel Schembri, David Hawkins, Andy Williams, Richard Gilson
Objectives: Post-exposure prophylaxis (PEP) for HIV is often poorly tolerated and not completed. Alternative PEP regimens may improve adherence and completion, aiding HIV prevention. We conducted a randomized controlled trial of a maraviroc-based PEP regimen compared with a standard-of-care regimen using ritonavir-boosted lopinavir. Methods: Patients meeting criteria for PEP were randomized to tenofovir disoproxil/emtricitabine (200/245 mg) once daily plus ritonavir-boosted lopinavir (Kaletra ® 400/100 mg) or maraviroc 300 mg twice daily...
June 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28276922/science-technology-power-and-sex-prep-and-hiv-positive-gay-men-in-paris
#8
Julien Brisson, Vinh-Kim Nguyen
The pre-exposure prophylaxis (PrEP) drug Truvada is a new HIV prevention technology that is predominantly promoted as relevant to HIV-negative gay men. This paper explores what PrEP represents for HIV-positive gay men living in Paris, based upon data collected through interviews and ethnographic research. While HIV-positive gay men do not directly consume Truvada through PrEP, they nonetheless hold opinions and understandings of this drug, specifically as it relates to their own sexuality. This paper expands the representations and meanings of this new technology in a different light through the voices of gay men living with HIV in Paris...
February 21, 2017: Culture, Health & Sexuality
https://www.readbyqxmd.com/read/28260694/a-case-study-of-chewed-truvada-%C3%A2-for-prep-maintaining-protective-drug-levels-as-measured-by-a-novel-urine-tenofovir-assay
#9
Linden Lalley-Chareczko, Devon Clark, Athena F Zuppa, Ganesh Moorthy, Caitlin Conyngham, Karam Mounzer, Helen Koenig
Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF; Truvada(®)) given as pre-exposure prophylaxis (PrEP) successfully blocks HIV when taken once daily prior to potential HIV exposure. A 22-year-old male reported difficulty swallowing FTC/TDF for PrEP and subsequently began chewing the FTC/TDF tablets. Monthly urine samples assessed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) indicated tenofovir levels >1,000 ng/ml, indicative of protection from HIV acquisition, over a 48-week period...
March 6, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28135199/pre-exposure-prophylaxis-prep-as-an-additional-tool-for-hiv-prevention-among-men-who-have-sex-with-men-in-belgium-the-be-prep-ared-study-protocol
#10
Irith De Baetselier, Thijs Reyniers, Christiana Nöstlinger, Kristien Wouters, Katrien Fransen, Tania Crucitti, Chris Kenyon, Jozefien Buyze, Céline Schurmans, Marie Laga, Bea Vuylsteke
BACKGROUND: Pre-exposure prophylaxis (PrEP) is a promising and effective tool to prevent HIV. With the approval of Truvada as daily PrEP by the European Commission in August 2016, individual European Member states prepare themselves for PrEP implementation following the examples of France and Norway. However, context-specific data to guide optimal implementation is currently lacking. OBJECTIVE: With this demonstration project we evaluate whether daily and event-driven PrEP, provided within a comprehensive prevention package, is a feasible and acceptable additional prevention tool for men who have sex with men (MSM) at high risk of acquiring HIV in Belgium...
January 30, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28130774/pre-exposure-prophylaxis-for-hiv-prevention-safety-concerns
#11
REVIEW
Raymond A Tetteh, Barbara A Yankey, Edmund T Nartey, Margaret Lartey, Hubert G M Leufkens, Alexander N O Dodoo
Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry " http://www...
April 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/27974330/post-exposure-prophylaxis-guidelines-for-children-and-adolescents-potentially-exposed-to-hiv
#12
Alasdair Bamford, Gareth Tudor-Williams, Caroline Foster
UK guidelines for HIV post-exposure prophylaxis (PEP) in adults have recently been updated. Indications for PEP have been modified and there has been a change in the recommended antiretroviral therapy for adults to a combination of raltegravir with tenofovir and emtricitabine (Truvada). Raltegravir and tenofovir are now available in paediatric formulations and offer improved safety and tolerability over previously recommended ritonavir-boosted lopinavir with zidovudine. This guideline provides recommendations for those caring for children potentially exposed to HIV and other bloodborne viruses in primary care, emergency departments, secondary care and specialist paediatric HIV centres...
January 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/27918570/hiv-pre-exposure-prophylaxis-is-it-just-about-pills
#13
Jose V Fernandez-Montero
The increasing use of antiretrovirals for averting HIV infection before potential exposure is under debate. Whereas there is no doubt about the benefit of using Truvada® (tenofovir plus emtricitabine) to reduce HIV acquisition in uninfected persons who have sex with HIV-infected stable partners, concerns are rising about the increasing rate of sexually transmitted infections in subjects engaged in sex with multiple partners, due to misinterpreted self-security.
October 2016: AIDS Reviews
https://www.readbyqxmd.com/read/27800524/slow-cd4-t-cell-recovery-in-human-immunodeficiency-virus-hepatitis-b-virus-coinfected-patients-initiating-truvada-based-combination-antiretroviral-therapy-in-botswana
#14
Motswedi Anderson, Simani Gaseitsiwe, Sikhulile Moyo, Kerapetse P Thami, Terence Mohammed, Ditiro Setlhare, Theresa K Sebunya, Eleanor A Powell, Joseph Makhema, Jason T Blackard, Richard Marlink, Max Essex, Rosemary M Musonda
Background.  Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection has emerged as an important cause of morbidity and mortality. We determined the response to Truvada-based first-line combination antiretroviral therapy (cART) in HIV/HBV-coinfected verus HIV-monoinfected patients in Botswana. Methods.  Hepatitis B virus surface antigen (HBsAg), HBV e antigen (HBeAg), and HBV deoxyribonucleic acid (DNA) load were determined from baseline and follow-up visits in a longitudinal cART cohort of Truvada-based regimen...
September 2016: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/27760684/preventing-hiv-among-adolescents-with-oral-prep-observations-and-challenges-in-the-united-states-and-south-africa
#15
Sybil Hosek, Connie Celum, Craig M Wilson, Bill Kapogiannis, Sinead Delany-Moretlwe, Linda-Gail Bekker
INTRODUCTION: Adolescents and young adults aged <25 are a key population in the HIV epidemic, with very high HIV incidence rates in many geographic settings and a large number who have limited access to prevention services. Thus, any biomedical HIV prevention approach should prepare licensure and implementation strategies for young populations. Oral pre-exposure prophylaxis (PrEP) is the first antiretroviral-based prevention intervention with proven efficacy across many settings and populations, and regulatory and policy approvals at global and national levels are occurring rapidly...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27749110/reactions-and-receptivity-to-framing-hiv-prevention-message-concepts-about-pre-exposure-prophylaxis-for-black-and-latino-men-who-have-sex-with-men-in-three-urban-us-cities
#16
Matthew J Mimiaga, Elizabeth F Closson, Shanice Battle, Jeffrey H Herbst, Damian Denson, Nicole Pitts, Jeremy Holman, Stewart Landers, Gordon Mansergh
Men who have sex with men (MSM) of color are disproportionately affected by HIV in the United States. Pre-exposure prophylaxis (PrEP) using antiretroviral medications is a newer biomedical prevention modality with established efficacy for reducing the risk of acquiring HIV. We conducted formative qualitative research to explore audience reactions and receptivity to message concepts on PrEP as part of the development of prevention messages to promote PrEP awareness among black and Latino MSM in the United States...
October 2016: AIDS Patient Care and STDs
https://www.readbyqxmd.com/read/27704821/discovery-and-development-of-the-anti-human-immunodeficiency-virus-drug-emtricitabine-emtriva-ftc
#17
Dennis C Liotta, George R Painter
The HIV/AIDS epidemic, which was first reported on in 1981, progressed in just 10 years to a disease afflicting 10 million people worldwide including 1 million in the US. In 1987, AZT was approved for treating HIV/AIDS. Unfortunately, its clinical usefullness was severly limited by associated toxicities and the emergence of resistance. Three other drugs that were approved in the early 1990s suffered from similar liabilities. In 1990, the Liotta group at Emory University developed a highly diastereoselective synthesis of racemic 3'-thia-2',3'-dideoxycytidine and 3'-thia-2',3'-5-fluorodideoxycytidine and demonstrated that these compounds exhibited excellent anti-HIV activity with no apparent cytotoxicity...
October 5, 2016: Accounts of Chemical Research
https://www.readbyqxmd.com/read/27632233/an-hiv-preexposure-prophylaxis-demonstration-project-and-safety-study-for-young-msm
#18
Sybil G Hosek, Bret Rudy, Raphael Landovitz, Bill Kapogiannis, George Siberry, Brandy Rutledge, Nancy Liu, Jennifer Brothers, Kathleen Mulligan, Gregory Zimet, Michelle Lally, Kenneth H Mayer, Peter Anderson, Jennifer Kiser, James F Rooney, Craig M Wilson
BACKGROUND: Young men who have sex with men (YMSM) are a key population for implementation of preexposure prophylaxis (PrEP) interventions. This open-label study examined adherence to PrEP and assessed sexual behavior among a diverse sample of YMSM in 12 US cities. METHODS: Eligible participants were 18- to 22-year-old HIV-uninfected MSM who reported HIV transmission risk behavior in the previous 6 months. Participants were provided daily tenofovir disoproxil fumarate/emtricitabine (Truvada)...
January 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27609216/prep-truvada-and-gilead
#19
Andrew Jack
No abstract text is available yet for this article.
September 8, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27295507/prep-on-twitter-information-barriers-and-stigma
#20
Joseph Schwartz, Josh Grimm
On May 14, 2014 the Centers for Disease Control and Prevention (CDC) endorsed the drug Truvada as an HIV preventative, called pre-exposure prophylaxis (PrEP). PrEP has been shown to dramatically reduce the risk of HIV infection, but its rate of adoption has been slow, and discourse surrounding it has been marked by stigma and uncertainty. The purpose of this study was to investigate how PrEP was discussed on Twitter. Our analysis focused on barriers to PrEP adoption and stigmatization of PrEP users. We analyzed a random sample of 1,093 top tweets about PrEP posted to Twitter a year before and a year after the CDC's endorsement...
April 2017: Health Communication
keyword
keyword
83063
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"